Efficacy and Safety of Ribupatide (KAI-9531) Administered Once Weekly in Participants Living With Obesity Who Do Not Have Diabetes

Running, not enrolling · Phase 2 · Has a placebo group

Conditions studied: Obesity

In brief

The primary objective of this study is to determine the effects of ribupatide administered by subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.

Key facts

Study ID
NCT07458269
Run by
Kailera
People needed
264
Starts
2026-03-04
Expected to finish
2027-06-01
Last updated by the study team
2026-07-15

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.